<DOC>
	<DOCNO>NCT00841217</DOCNO>
	<brief_summary>The purpose study determine whether PPAR-delta agonist ( GW5015156 ) favorable effect lipoprotein metabolism .</brief_summary>
	<brief_title>Regulation Lipoprotein Transport Metabolic Syndrome</brief_title>
	<detailed_description>The metabolic syndrome ( MetS ) portend diabetes cardiovascular disease ( CVD ) . Dyslipoproteinaemia , reflect elevated plasma triglyceride reduce high-density lipoprotein ( HDL ) concentration , cardinal feature MetS independently predict CVD accordingly therapeutic target risk reduction . GW5015156 new PPAR-delta agonist could use treat dyslipidemia insulin resistance obesity . However , precise mechanisms action agent lipoprotein kinetics MetS subject yet fully investigate . We therefore carry study study effect GW5015156 lipoprotein transport subject metabolic syndrome .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Any three following : Waist circumference &gt; 102 cm Triglycerides &gt; 150 mg/dL HDLcholesterol &lt; 40 mg/dL Blood glucose &gt; 110 mhg/dL Blood pressure &gt; 130/85 mmHg Triglycerides &gt; 500 mg/dL Diabetes mellitus CVD Consumption &gt; 30 g alcohol/day Use agent affect lipid metabolism APOE2/E2 genotype Creatinemia ( &gt; 120 umol/L ) Hypothyroidism Abnormal liver muscle enzyme</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Drug treatment</keyword>
</DOC>